Sign in
Taking peopleNo phase

Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication

Key facts

Who runs it
Peking University First Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
70 people, planned
Started
25 Apr 2026
Expected to end
13 Feb 2027
Type of study
Interventional
Treatments tested
  • Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days
Record updated
30 April 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Aged 18-70 years
  • Positive results for both ¹³C-urea breath test (¹³C-UBT) and fecal polymerase chain reaction (PCR), confirming Helicobacter pylori infection, with a clinical indication for H. pylori eradication as judged by the physician
  • Treatment-naïve individuals with no prior history of H. pylori eradication therapy

Who cannot take part

  • Patients with a history of allergy to any drugs used in the eradication regimen
  • Patients with severe systemic diseases or malignant tumors
  • History of gastric resection surgery
  • Recent use of antibiotics or bismuth salts (within 4 weeks), H₂-receptor antagonists, proton pump inhibitors (PPIs), or Potassium-competitive acid blockers(P-CABs) (within 2 weeks)
  • Pregnant or lactating women

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.

The group in the trial

  • ExperimentalTreatment being tested

    Vonoprazan 20mg twice a day + clarithromycin 500mg twice a day

    Treatment: Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Simplified Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line Helicobacter Pylori Eradication
Criteria questions
Built from NCT07439445, who can take part
Record updated
30 April 2026